Form 4: Allogene Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Timothy L. Moore, Chief Technical Officer of Allogene Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On February 3, 2025, Timothy L. Moore, the Chief Technical Officer of Allogene Therapeutics, Inc. (ALLO), sold 14,746 shares of common stock at a price of $1.71 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Moore directly owns 250,713 shares of Allogene Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell to cover taxes) and doesn't contain information that would significantly sway investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder perception, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| June 17, 2024 | Date of Power of Attorney execution. |
| February 3, 2025 | Date of the share sale transaction. |
| February 5, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.